iPSC vaccines target shared antigens between iPSCs and cancer cells


iPSC vaccines promote a humoral and cell-mediated anti-tumor immune profile


As an adjuvant cancer therapy, iPSC vaccination can reactivate the immune system

Riepilogo

Cancer cells

and embryonic tissues share a number of cellular and molecular properties, suggesting that induced pluripotent stem cells (iPSC) may be harnessed to elicit anti-tumor responses in cancer vaccines. RNA sequencing revealed that human and murine iPSCs express tumor-associated antigens, and we show here a proof of principle for using irradiated iPSCs in autologous anti-tumor vaccines. In a prophylactic setting, iPSC vaccines prevent tumor growth in syngeneic murine breast cancer, mesothelioma, and melanoma models.

As an adjuvant, the iPSC vaccine inhibited melanoma recurrence at the resection site and reduced metastatic tumor load, which was associated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells. Adoptive transfer of T cells isolated from vaccine-treated tumor-bearing mice inhibited tumor growth in unvaccinated recipients, indicating that the iPSC vaccine promotes an antigen-specific anti-tumor T cell response. Our data suggest an easy, generalizable strategy for multiple types of cancer that could prove highly valuable in clinical immunotherapy.

 

Parole chiave
#pluripotentstemcells

immunotherapy prophylactic vaccination adjuvant therapy shared epitopes breast cancer melanoma mesothelioma metastases immune profiling

 

sciencedirect.com

 

 


NBScienza

organizzazione di ricerca a contratto

terapia con cellule staminali